Advertisement
AMGN vs GILD
Which Stock Would AI Choose? Amgen (AMGN) vs. Gilead Sciences (GILD) Stock Comparison
Key Takeaways
- Amgen (AMGN) delivered Q1 2026 revenue of $8.62 billion, up 5.8% year-over-year, but shares have faced recent pressure amid regulatory scrutiny.
- Gilead Sciences (GILD) shows stronger year-to-date performance at approximately 7.9%, outperforming AMGN's roughly 1.5% gain.
- Both stocks trade in the biotech sector with solid dividends, but GILD offers a lower price-to-earnings (P/E) ratio of about 19.4 versus AMGN's 22.9.
- Recent technical indicators suggest potential oversold bounces for GILD, while AMGN shows mixed bearish signals amid pipeline optimism.
- GILD benefits from HIV franchise strength and oncology expansions, contrasting AMGN's focus on obesity and inflammation drugs.
Introduction
Amgen (AMGN) and Gilead Sciences (GILD), two biotech powerhouses, offer investors exposure to innovative pharmaceuticals amid evolving healthcare demands. This comparison analyzes their recent market performance, financial metrics, and growth drivers, aiding traders seeking relative value in the sector and long-term holders eyeing dividend stability. With both navigating patent challenges and pipeline advancements, understanding their head-to-head dynamics supports informed decisions in a volatile biotech landscape.
AMGN Overview and Recent Performance
Amgen Inc. (AMGN) is a leading biotechnology firm specializing in oncology, inflammation, and rare diseases, with key products like Enbrel and Prolia. In recent market activity, shares have traded around $330, reflecting a year-to-date gain of about 1.5% but recent weakness, including a 4.75% drop in early May. Q1 2026 results showed revenue of $8.62 billion, a 5.8% increase year-over-year, driven by double-digit growth across 16 products, though adjusted EPS of $5.15 slightly beat estimates. Sentiment has been influenced by FDA scrutiny on its drug Tavneos (an inflammation treatment acquired via Horizon Therapeutics) and looming patent expirations, offsetting optimism around obesity candidate MariTide and AI-enhanced R&D. The stock's 52-week range spans $261 to $391, with a market cap near $178 billion.
GILD Overview and Recent Performance
Gilead Sciences Inc. (GILD) focuses on antivirals, HIV therapies like Biktarvy, and expanding oncology offerings. Shares recently hovered near $132, with a solid year-to-date return of approximately 7.9% but a 1.6% dip over the past 30 days. The stock's 52-week range is $95 to $157, supported by a $163 billion market cap. Recent performance reflects resilience from HIV franchise growth and strategic acquisitions bolstering the pipeline, alongside FDA priority review for new HIV treatments. Upcoming earnings are anticipated to highlight oncology momentum, though sector volatility and interest rate sensitivity have tempered gains. Technical oversold conditions signal potential rebound opportunities.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from over 350 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—from short-term scalping (5-60 minutes) to swing trading—showcasing annualized returns ranging from 30% to over 126%, win rates of 50-88%, and profit factors up to 7.1. Selected for current market conditions like volatility in semiconductors, data centers, and small caps, the 25 trending bots demonstrate profit-to-drawdown ratios often exceeding 5:1, with average trade durations from hours to weeks. Traders can copy these high-performing models tailored to sectors gaining traction, offering data-driven edges in dynamic environments. Explore the page to identify bots aligning with your timeframe and risk profile.
Head-to-Head Comparison
Amgen (AMGN) and Gilead Sciences (GILD) share biotech roots but diverge in focus: AMGN emphasizes inflammation and emerging obesity therapies, while GILD leads in virology with oncology diversification. Growth drivers include AMGN's pipeline breadth and GILD's M&A activity (mergers and acquisitions). Recent momentum favors GILD with superior YTD returns and oversold technicals, versus AMGN's post-earnings pullback. Risk factors involve patent cliffs for both, though AMGN faces nearer-term regulatory hurdles. Sector exposure is similar in major pharmaceuticals, but GILD's lower P/E (19.4 vs. 22.9) suggests better valuation, with market sentiment tilting toward GILD's stability amid volatility.
Tickeron AI Verdict
Tickeron’s AI currently favors Gilead Sciences (GILD) over Amgen (AMGN), based on stronger year-to-date momentum, attractive valuation metrics, and technical patterns indicating an oversold bounce with upward trend potential. While AMGN boasts robust Q1 growth and pipeline catalysts, GILD's relative stability and lower risk-reward profile position it for higher near-term outperformance probability in the current biotech environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and GILD is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 3 FA rating(s) are green whileGILD’s FA Score has 3 green FA rating(s).
- AMGN’s FA Score: 3 green, 2 red.
- GILD’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while GILD’s TA Score has 5 bullish TA indicator(s).
- AMGN’s TA Score: 4 bullish, 4 bearish.
- GILD’s TA Score: 5 bullish, 3 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +0.57% price change this week, while GILD (@Pharmaceuticals: Major) price change was -0.24% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.10%. For the same industry, the average monthly price growth was +0.24%, and the average quarterly price growth was +6.99%.
Reported Earning Dates
AMGN is expected to report earnings on Jul 30, 2026.
GILD is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.10% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | GILD | AMGN / GILD | |
| Capitalization | 179B | 163B | 110% |
| EBITDA | 16.7B | 13.6B | 123% |
| Gain YTD | 2.043 | 7.606 | 27% |
| P/E Ratio | 22.90 | 17.87 | 128% |
| Revenue | 37.2B | 29.4B | 127% |
| Total Cash | 12B | N/A | - |
| Total Debt | 57.3B | 24.9B | 230% |
AMGN | GILD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 17 Undervalued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 32 | 13 | |
SMR RATING 1..100 | 13 | 23 | |
PRICE GROWTH RATING 1..100 | 58 | 53 | |
P/E GROWTH RATING 1..100 | 62 | 67 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (17) in the Biotechnology industry is in the same range as GILD (18). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.
GILD's Profit vs Risk Rating (13) in the Biotechnology industry is in the same range as AMGN (32). This means that GILD’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's SMR Rating (13) in the Biotechnology industry is in the same range as GILD (23). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.
GILD's Price Growth Rating (53) in the Biotechnology industry is in the same range as AMGN (58). This means that GILD’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's P/E Growth Rating (62) in the Biotechnology industry is in the same range as GILD (67). This means that AMGN’s stock grew similarly to GILD’s over the last 12 months.
| AMGN | GILD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 59% | 1 day ago 56% |
| Stochastic ODDS (%) | 1 day ago 53% | 1 day ago 50% |
| Momentum ODDS (%) | 1 day ago 47% | 1 day ago 59% |
| MACD ODDS (%) | 1 day ago 40% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 58% | 1 day ago 44% |
| TrendMonth ODDS (%) | 1 day ago 49% | 1 day ago 48% |
| Advances ODDS (%) | 4 days ago 56% | 4 days ago 61% |
| Declines ODDS (%) | 6 days ago 51% | 1 day ago 46% |
| BollingerBands ODDS (%) | 1 day ago 62% | 1 day ago 44% |
| Aroon ODDS (%) | 1 day ago 51% | 1 day ago 54% |
Advertisement